Smith & Nephew (LON:SN – Get Free Report)‘s stock had its “overweight” rating reissued by JPMorgan Chase & Co. in a research note issued on Thursday, LSE.Co.UK reports. They currently have a GBX 1,248 ($15.76) target price on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 22.17% from the stock’s […]
A no-brainer FTSE 100 stock to buy and hold for the next decade? fool.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.co.uk Daily Mail and Mail on Sunday newspapers.
Smith+Nephew To Buy Agili-C Developer CartiHeal In Up To $330 Mln Deal finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Smith & Nephew PLC (LSE:SN) has announced the acquisition of knee cartilage regeneration technology developer CartiHeal. Under the agreement, the FTSE.